Carvedilol is a clinically effective β-blocker broadly used for treating congestive heart failure (CHF), and several clinical trials have demonstrated that it shows a favourable effect compared with other β-blockers in patients with CHF. The mechanism underlying this beneficial effect of carvedilol compared to other β-blockers is not clearly understood. In addition to β-blockers, inhibitors of hyperpolarization-activated cyclic nucleotide (HCN)-gated channels, which play a critical role in spontaneous rhythmic activity in the heart, have also been proposed to be suitable drugs for reducing heart rate and, therefore, beneficial for treating CHF. In the present study, we investigated the effect of carvedilol on HCN channels.
Introduction
Hyperpolarization-activated cyclic nucleotide (HCN)-gated channels play a central role in the spontaneous rhythmic activity in both the heart and nervous system (Biel et al., 2009) . The current mediated by HCN channels is called I f or I h in the sinoatrial node and neuronal cells respectively. In the heart, I f is a major determinant of cardiac diastolic depolarization and is crucial in controlling the heart rate. Four isoforms of HCN channels (HCN1-HCN4) exist in mammals with different biophysical properties and diverse tissue expression (Gauss et al., 1998; Ludwig et al., 1998; Biel et al., 2009) . Among them, HCN4 is the principle isoform that mediates I f , while the expression of other isoforms is significantly weaker and species-dependent (Shi et al., 1999; Fürst and D'Avanzo, 2015) . In the nervous system, HCN channels are widely expressed, involved in neuronal excitability and network activity, and have been reported to participate in several physiopathological processes, including dendritic integration, synaptic transmission, spatial working memory, hydroelectrolyte homeostasis, epilepsy, inflammatory and neuropathic pain (Wang et al., 2007; Benarroch, 2013; Pires da Silva et al., 2016) . Finding modulators that target HCN channels may be an important strategy for treatment of congestive heart failure (CHF), arrhythmias, epilepsy and pain (Postea and Biel, 2011) . One such HCN channel blocker, ivabradine, was approved by the Food and Drug Administration (FDA) to treat chronic heart failure in 2015 (U.S. Food and Drug Administration, 2015) .
Topologically, HCN channels belong to the superfamily of voltage-gated potassium (K v ) and cyclic nucleotideregulated channels. Each subunit contains six transmembrane domains (S1-S6), a re-entrant loop between the S5-S6 helices that forms the selectivity filter and pore, and a cytosolic cyclic nucleotide-binding domain (CNBD) attached to S6 via an 80 amino acid C-linker (Zagotta et al., 2003; Xu et al., 2010; Cao et al., 2016) . Characteristic electrophysiological properties of HCN channel include activation on hyperpolarization, conduction of both Na + and K + and inhibition by mM concentrations of external Cs + (Robinson and Siegelbaum, 2003; Biel et al., 2009) . Another property of HCN channels is their direct modulation by cAMP/cGMP, which shifts the channels' open probability towards more depolarized voltages and accelerates their activation speed (Gauss et al., 1998; Ludwig et al., 1999; Santoro and Tibbs, 1999) . Carvedilol (chemical structure in Figure 1A ), a third generation β-adrenoceptor blocker, is one of the most extensively studied and effective β-blockers for preventing CHF. Several multi-centre, placebo-controlled clinical trials have shown that carvedilol reduces the risk of death and hospitalization from cardiovascular causes in patients with mild to moderate and severe CHF Packer et al., 1996; Weir and Dargie, 2005) . Furthermore, another large randomized clinical trial, COMET, demonstrated that carvedilol shows favourable benefits to CHF patients compared with metoprolol (Poole- Wilson et al., 2003; DiNicolantonio and Hackam, 2012) . The mechanism underlying the favourable effects of carvedilol compared to other β-blockers is still not completely clear. In addition to blocking β receptors, carvedilol also shows a broad range of other activities, such as blocking α-adrenoceptors and has antioxidant properties (Stroe and Gheorghiade, 2004; Weir and Dargie, 2005) . It has been suggested that carvedilol's non-selectivity and additional properties maybe important for treatment of CHF. Since HCN channels play a critical role in spontaneous rhythmic activity in the heart, the effect of carvedilol on HCN channels was investigated in our present study.
The effect of several broadly used β-blockers (carvedilol, metoprolol, bisoprolol and labetalol) on HCN4 channel was also examined, and only carvedilol demonstrated an inhibitory effect on HCN4 currents. The mechanism of action of carvedilol on HCN channels was further characterized in the present study.
Methods

Group size
The size (n) for each experimental group and the total number (N) of cells are provided in the figures and tables. The n refers to different transfections, and at least two cells were recorded for each transfection. The N refers to the total number of cells for each experimental group. Data subjected to statistical analysis had an n of at least five for each group.
Randomization
Randomization was not performed as this is not a standard procedure in electrophysiological recordings.
Blinding
Blinding of experiments is not applicable. However, when comparisons were made between wild-type (WT) and mutant channels, the transfection and electrophysiological recordings were conducted by different people. The electrophysiological recordings and data collection were accomplished by an operator who was blinded to the transfection.
Cell culture and transfection
CHO cells were cultured in 50/50 DMEM/Ham's F-12 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS in 35 mm dishes and incubated at 37°C with 5% CO 2 . At 80-90% confluence, plasmids expressing eGFP as a marker and the channel cDNAs of HCN1 (from human), HCN2 (from mouse and human) or HCN4 (from mouse and human) were cotransfected into the CHO cells using 10 μL Lipofectamine 2000 (Life Technologies) with a ratio of 1:9. Then, 24 h after transfection, the cells were split by trypsin-EDTA and replated onto 10 mm coverslips coated with 0.1 mg·mL À1 poly-L-lysine (Sigma-Aldrich, St. Louis, MO, USA) for electrophysiological experiments.
Mutagenesis
QuikChange (Agilent, Waldbronn, Germany) was used to introduce mutations into mHCN2 or mHCN4. To delete the CNBD and extreme C-terminus of mHCN4 (HCN4△CNBD), a stop codon was introduced after residue F603 (V604stop) as described previously (Wainger et al., 2001) . Eight mutants including four mHCN2 mutants (A425G, Y428A, F431A and I432A) and four mHCN4 mutants (Y506A, F509A, I510A and △CNBD) were constructed. All clones were verified by further DNA sequencing of the complete ORF.
Figure 1
The β-blocker carvedilol inhibits the HCN4 channel. (A) Structures of carvedilol, metoprolol, bisoprolol and labetalol. (B) Examples of the mHCN4 currents in the absence and presence of the tested compound (10 μM). Currents were elicited by a 2 s hyperpolarizing step to À120 mV from a holding potential of À40 mV, tail currents were measured at +50 mV and the protocol was applied every 15 s. The activation (at À120 mV) and deactivation (at +50 mV) kinetics were fitted with single exponential equations and labelled in red. To evaluate the effect of cAMP on the WT and mutant HCN channels, 100 μM 8-Br-cAMP (Sigma-Aldrich) was added to the intracellular solution. The extracellular solution was composed of 140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1.5 mM MgCl 2 , 10 mM HEPES and 10 mM glucose (pH adjusted to 7.4 with NaOH). Carvedilol, ivabradine, metoprolol, bisoprolol and labetalol (Sigma-Aldrich) were dissolved in DMSO to make 100 mM stock solutions that were stored at À20°C. On the day of the experiments, the stock solutions were diluted in extracellular solution to the final desired concentrations. During the experiments, a constant perfusion of bath solution (control or test solution) was delivered by a homemade perfusion device allowing rapid solution switches with a flow velocity approximately 2 mL·min À1 .
Data analysis and statistics
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Electrophysiological data were processed using Clampfit 10.6 (Molecular Devices) and further analysed in GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA).
The activation (at À120 mV) and deactivation (at +50 mV) kinetics were fitted with single exponential equation using Clampfit 10.6. Voltage-dependent activation curves for HCN channels were fitted with the Boltzmann equation,
, where G max is the maximum conductance, G min is the minimum conductance, V 0.5 is the half-activation voltage and S is the slope factor. In the fit, the top and the bottom of the curve was allowed to vary. Dose-response curves were fitted to the Hill equation, △V 0.5 = △V 0.5 max + △V 0.5 max [1 + (C/EC 50 ) nH ], where △V 0.5 = V 0.5 drug À V 0.5 control , EC 50 corresponds to a drug concentration producing half of the maximum shift in V 0.5 , [C] corresponds to the drug concentration and n H is the Hill coefficient. Data are presented as the mean ± SEM of N (total number of cells). Differences between groups were compared by Student's t-tests. Comparisons between three groups were performed by using one-way ANOVA. A P value <0.05 was considered as statistically significant.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Inhibition of HCN4 channel by carvedilol
Given that HCN4 is the most abundant subunit expressed in the heart, we first investigated the action of several clinically, broadly used and structurally diverse β-blockers (chemical structures in Figure 1A ) for their effects on mHCN4 channel. Among the β-blockers tested in our system, only carvedilol displayed significant modulation of the mHCN4 currents at 10 μM ( Figure 1B ,C) or 30 μM (Supporting Information Figure S1A ,B). Perfusion of 10 μM carvedilol reversibly suppressed the current by 44.6 ± 2.2% at À120 mV ( Figure 1C) . Figure 1D shows a comparison of the mHCN4 currents elicited from À50 to À140 mV in the absence or presence of 10 μM carvedilol. Carvedilol demonstrated inhibitory effects on mHCN4 in three aspects. Firstly, 10 μM carvedilol strongly left shifted the voltage-dependence of activation to the left by roughly 27 mV ( Figure 1E and Table 1) , and a similar effect was observed for hHCN4 (Supporting Information Figure S2A,B) . Secondly, the observed onset of blockage by carvedilol was rapid, reversible and not accompanied by any significant change in membrane capacitance ( Figure 1F ). Thirdly, the compound decelerated the activation and accelerated the deactivation process dramatically. Channel activation was much slower in the presence of 10 μM carvedilol ( Figure 1G ). On the other hand, 10 μM carvedilol decreased the deactivation time constant of mHCN4 ( Figure 1H) . Furthermore, the dose-response relationship showed that the EC 50 of carvedilol was 4.4 ± 1.2 μM on the mHCN4 channel with a Hill coefficient of 3.2 ± 1.6 ( Figure 1I and Table 2 ). Table 1 V 0.5 and slope factors of HCN channels in the absence and presence of 10 μM carvedilol Channel Control 10 μM carvedilol
Slope factor V 0.5 (mV) Slope factor hHCN1 À67.7 ± 0.4 6.3 ± 0.4 À93.6 ± 1.1 8.3 ± 1.0 À24.4 ± 1.8 6/18 mHCN2 À97.1 ± 0.5 6.2 ± 0.5 À115.8 ± 1.4 7.5 ± 1.1 À17.7 ± 0.7 6/18 mHCN4 À104.0 ± 0.9 8.7 ± 0.8 À128.8 ± 6.2 10.9 ± 2.8 À26.8 ± 1.8 6/18
Effect of carvedilol on HCN4 channels is not dependent on either cAMP or the CNBD region
As demonstrated before, intracellular cAMP shifts the G-V curve of HCN channels to the depolarized direction and accelerates the activation of HCN channels, thereby promoting the activation of HCN channels. To further investigate whether the inhibition caused by carvedilol is relevant to alterations in endogenous cAMP concentrations or the CNBD region, we assessed the effect of carvedilol on the cAMPinsensitive HCN4 mutant, HCN4△CNBD channel (Wainger et al., 2001 ). An application of 100 μM 8-Br-cAMP via the patch pipette shifted the voltage-dependent activation curve of mHCN4 towards a more positive potential, which is similar to earlier reports (△V 0.5 = 10.4 ± 1.8 mV, Figure 2A ,B) (Ludwig et al., 1998) . In contrast to the WT channel, no significant change was observed for mHCN4△CNBD under the same condition (△V 0.5 = 2.0 ± 1.5 mV, Figure 2A ,B) (Wainger et al., 2001) . Figure 2C shows a comparison of HCN4△CNBD-mediated currents elicited from À50 to À140 mV in the absence or presence of 10 μM carvedilol. The 10 μM carvedilol strongly shifted the voltage-dependence of the activation to the left by approximately 40 mV on mHCN4△CNBD ( Figure 2D ). In addition, the drug also increased the activation time constant by fivefold and decreased the deactivation time constant by 2.5-fold on mHCN4△CNBD ( Figure 2E ). We also examined the blockage effect of carvedilol on the mHCN4 WT channel when 100 μM 8-Br-cAMP was added into the intracellular solution. The △V 0.5 induced by 10 μM carvedilol was À28.2 mV ( Figure 2F and Supporting Information Figure S3 ) when 100 μM 8-Br-cAMP was added intracellularly. The shift of V 0.5 was similar regardless of whether 8-Br-cAMP was included in the intracellular solution.
The above results demonstrated that the inhibitory effect of carvedilol on mHCN channels in the CHO cells was not related to cellular cAMP concentration or the CNBD region of the channel and thus is not the result of its β-blocking activity.
Blockade of HCN1 and HCN2 channels by carvedilol
To assess the potency and selectivity of carvedilol towards other HCN isoforms, we individually expressed hHCN1 and mHCN2 channel in CHO cells to evaluate their sensitivity to carvedilol. Figure 3A ,D shows the representative current traces of hHCN1 and mHCN2 in the absence and presence of 10 μM carvedilol. For the hHCN1 channel, carvedilol shifted the voltage-dependence of activation to the left by 24.4 mV ( Figure 3B ,G and Table 1 ). In addition, 10 μM carvedilol shifted the voltage-dependence of activation to the left by 17.7 mV in mHCN2 ( Figure 3E ,G and Table 1) , and a similar effect was observed in the hHCN2 (Supporting Information Figure S2C,D) . Furthermore , dose-response curve analysis determined that the EC 50 of carvedilol was 7.9 ± 1.2 μM for hHCN1 (H = 2.1 ± 1.0) and 7.6 ± 1.1 μM for mHCN2 (H = 2.4 ± 0.7) respectively ( Figure 3C ,F and Table 2 ). Moreover, carvedilol also decreased the activation and increased the deactivation times of both the hHCN1 and mHCN2 channels ( Figure 3H,I ), which were similar its effects on mHCN4.
Mechanistic characterization of carvedilol modulation of HCN4 channels
Previous studies have shown that ivabradine is an 'openchannel' blocker of HCN4, which indicates that both the blockade by ivabradine and block removal require channel opening (Bucchi et al., 2002; Bucchi et al., 2013) . Next, we examined whether or not carvedilol was an 'open-channel' inhibitor of HCN4 channels. Figure 4A shows the results of an experiment to test whether carvedilol could bind to the mHCN4 channel when the channel was closed. When carvedilol was applied, the repetitive activation/deactivation protocol (À120/+50 mV) was interrupted, and the cell was held under À30 mV during which the channels were predominantly closed. The pulsing protocol was then resumed after a 150 s perfusion with carvedilol. We found that the extent of the blockage induced by 10 μM carvedilol in the absence of mHCN4 activation (46.8 ± 4.5%) was similar to that when the channels were activated every 15 s throughout the carvedilol application, as shown in Figure 1 (44.6 ± 2.2%).
On the other hand, we also examined whether the blockade effect of carvedilol could be removed when the channel was closed ( Figure 4B ). Following the steady suppression by carvedilol on mHCN4, the membrane voltage was held at À30 mV, and the drug was washed off for 150 s. Then, the train stimulation was resumed and still in the absence of carvedilol. The current was almost immediately fully recovered under this condition, showing that block removal could occur under the closed-state channel conformation. In addition, we used a prolonged 50 s activation protocol and applied carvedilol under the steady-state condition, and the results indicated the blockade effect could not occur during steady-state activation ( Figure 4C ). In contrast to an obvious inhibitory effect of carvedilol demonstrated within 50 s of its perfusion using the repetitive activation/deactivation protocol ( Figure 1F ), the current ratio before and after the perfusion of 10 μM carvedilol was nearly 1 as shown in Figure 4C (n = 5). Overall, the above results indicate carvedilol does not preferentially bind to the open state of the HCN channel, which is different from that of ivabradine (Bucchi et al., 2006) .
Distinct interaction sites of carvedilol compared with ivabradine
We next set out to characterize the molecular mechanism by which carvedilol blocks HCN channels. We investigated whether carvedilol and ivabradine compete for the same sites to suppress HCN currents. Previous studies have identified several residues important for conferring sensitivity to ivabradine or ZD7288 in HCN4 and HCN2 subtypes (Cheng et al., 2007; Bucchi et al., 2013) . The amino acids identified for ivabradine and ZD7288 sensitivity are mainly located in the pore region (S5-P-S6 region): Y506, F509 and I510 in mHCN4 for ivabradine and A425 and I432 in mHCN2 for ZD7288 ( Figure 5A ). Given that none of the constructs produced large enough currents when mutated in mHCN4 channel in our experimental system, we systematically mutated the corresponding residues in mHCN2 channel (A425G, Y428A, F431A and I432A) and compared the sensitivity of carvedilol on WT and mutant channels. Among the four mutant channels, Y428A and I432A could not generate large enough currents to evaluate the inhibitory effect of carvedilol. Therefore, we compared carvedilol's action on WT, A425G and F431A mHCN2 channels. The mutation of mHCN4 F509A (corresponding to mHCN2 F431A) dramatically reduced the effect of ivabradine compared with the WT channel (Cheng et al., 2007) . Another study showed that the sensitivity of ZD7288 on HCN2 was much less than A425G compared with the WT channel (Bucchi et al., 2013) . In contrast to these results, our study showed carvedilol exerted similar inhibitory effects on the WT and mutant channels by reducing the current at À120 mV ( Figure 5B,C) and strongly shifting the voltage-dependence of activation Figure 3 Subtype selectivity of carvedilol. Whole-cell currents of (A) hHCN1 and (D) mHCN2 were recorded in the absence (upper panel) and presence (bottom panel) of 10 μM carvedilol. Voltage-dependent activation curves of (B) hHCN1 and (E) mHCN2 in the absence and presence of 10 μM carvedilol as indicated. Dose-response curves of carvedilol on the (C) hHCN1 and (F) mHCN2 channels obtained as in Figure 1I . (G) Bar graphs plotting the V 0.5 of hHCN1 and mHCN2 in the absence and presence of 10 μM carvedilol. (H) Activation time constant (τ act ) at À120 mV and (I) deactivation time constant (τ deact ) at +50 mV for hHCN1 and mHCN2 as indicated. The number of independent experiments/total number of cells (n/N) is indicated in parentheses at the top of graphs. *P < 0.05 versus control.
leftwards by approximately 20 mV on the mutant channels ( Figure 5E,F) , similar to the extent observed for WT channel ( Figure 5D ,G). These observations indicate that carvedilol may act by a different molecular mechanism from that of ivabradine or ZD7288 on HCN channels.
Discussion
Carvedilol blocks HCN channels
We showed here that carvedilol blocks HCN channels in a concentration-dependent manner with an EC 50 value of 4.4 μM on the major sinoatrial isoform HCN4. In addition, carvedilol also inhibited HCN1 and HCN2 currents. The effect of carvedilol on I f in the rabbit sinoatrial node was investigated previously, and an inhibition of I f was noted at μM concentrations of carvedilol (Yokoyama et al., 2007) , but the characteristics and biophysical mechanism of action were not studied there. We analysed the biophysical mechanism of the HCN inhibition induced by carvedilol in detail in our study. A rapid onset and reversible block supported the hypothesis that carvedilol is a direct channel inhibitor rather than acting via modulating protein trafficking or intracellular signalling pathways. Major effects caused by carvedilol include marked alterations in channel voltage-dependence and activation kinetics. For the HCN4 channel, 10 μM carvedilol decelerated the activation speed by threefold at À120 mV and shifted the V 0.5 leftwards by approximately 27 mV. Our study demonstrated that the inhibitory effects of carvedilol on HCN channels in CHO cells is unrelated to its β-adrenoceptor blocking property given that carvedilol still exerted dramatic inhibitory effects on cAMP-insensitive HCN4 mutant channels. In addition, carvedilol's block of HCN4 channels was also not affected by a saturated concentration of intracellular cAMP.
Recent progress of HCN channels structure-function study As mentioned before, the unique biophysical properties of HCN channels have strongly attracted the interest of researchers. In most K v channels, the voltage sensors are 'swapped', which indicates each voltage sensor contacts the pore through amino acids from a neighbouring subunit (Catterall, 2010; Bezanilla, 2000) . The domain-swapped voltage sensors and the long α-helical S4-S5 linker in most K v channels likely functions as a mechanical lever through which voltage sensor conformational changes impart a force to open or close the pore's gate. The cryo-electron microscopy (cryo-EM) structures of human HCN1 channels revealed that the voltage sensors are 'non-swapped' and the S4-S5 linker is not α-helical and much shorter in this channel (Lee and Mackinnon, 2017) . Thus, instead of using the S4-S5 linker Figure 4 Biophysical characterization of carvedilol blockage of mHCN4. (A) Time course of relative mHCN4 current at À120 mV during an activation/deactivation protocol (À120 mV/+50 mV) from a holding potential of À40 mV. At the beginning of the perfusion with 10 μM carvedilol, current stimulation was stopped by holding the membrane voltage at À30 mV for 150 s. (B) The same activation/deactivation protocol was applied in the presence of 10 μM carvedilol until a stable state of inhibition was reached. The cell was held at À30 mV, and carvedilol was washed off for 150 s. Then, the train of stimulation was resumed in the absence of carvedilol. (C) Effect of carvedilol on mHCN4 channel when it was applied during the steady-state activation. Carvedilol (10 μM) was applied for 30 s, and the mHCN4 currents were recorded at À120 mV. Similar experiments were repeated at least five times.
as a mechanical lever, it is proposed that HCN channels utilize the long S4 helix, which is unusual, for coupling to the pore to mediate the reversed polarity gating. HCN channels share the glycine-tyrosine-glycine motif, which is a signature selectivity filter for K + channels. However, HCN channels are non-selective monovalent cation channels, permitting K + over Na + at a ratio of~4:1 (Ludwig et al., 1998) .
High potassium selectivity in K + channels comes from the precise geometry of the selectivity with four ion binding sites (Zhou et al., 2001; Hille, 2018) . Interestingly, the first two ion binding sites are absent in HCN1 as revealed by the cryo-EM structure, which leads to the non-selectivity property of the channel (Lee and Mackinnon, 2017) . The four isoforms of HCN channels (HCN1-HCN4) differ in their voltagedependent gating properties (Biel et al., 2009; Cao et al., 2016) . Among them, the HCN1 channel has the most positive V 0.5 for activation and the fastest activation kinetics, while the HCN4 channel is the slowest voltage-gated isoform (Ludwig et al., 1998; Biel et al., 2009) . In addition, HCN2 and HCN3 subunits have intermediate biophysical properties compared with the other subtypes (Ludwig et al., 1998; Biel et al., 2009) . Differences in the extent of cAMP modulation between the HCN1 and HCN2 isoforms result largely from differences in the efficacy of CNBD inhibition from the C-terminus (Wainger et al., 2001) . In addition, regions in S1, S1-S2 loop and S2 have been reported to play key roles in different channel activation kinetics (Ishii et al., 2001; Stieber et al., 2003; Ishii et al., 2007) . The cryo-EM structure and extensive biophysical studies have provided a framework to investigate the molecular mechanism underlying HCN channel and inhibitor interaction in the future.
Carvedilol and previously reported HCN channel blockers
Two widely studied HCN blockers are ivabradine and ZD7288 (Sartiani et al., 2017) . Ivabradine was approved by the FDA for the treatment of CHF in 2015 (U.S. Food and Drug Administration, 2015) . It is used in combination with β-blockers in people with CHF with a left ventricular ejection fraction lower than 35% inadequately controlled by β-blockers alone and whose heart rate exceeds 70 beats min À1 (Müller-Werdan et al., 2016) . In patients not sufficiently managed with β-blockers for their heart failure, adding ivabradine decreases the risk of hospitalization due to worsening CHF (McMurray et al., 2012; Tse and Mazzola, 2015) . In addition to ivabradine, several other 'bradine' compounds also demonstrate inhibitory effects on HCN channels, including cilobradine and zatebradine (Postea and Biel, 2011) . Neither ivabradine nor ZD7288 shows subtype selectivity among HCN1-HCN4 channels (Stieber et al., 2006; Sartiani et al., 2017) . Furthermore, several blockers with high subtype selectivity have been found based on structure modification of known non-selective inhibitors or high-throughput screening (Melchiorre et al., 2010; Del Lungo et al., 2012) . Extensive studies have demonstrated that ivabradine blocks HCN channels from the intracellular side, and it is an 'open-channel' inhibitor since its effect can only occur after channel opening (Bucchi et al., 2002; Bucchi et al., 2013) . For ZD7288, it has been shown that ZD7288 blocks HCN1 channel only after they are opened by hyperpolarization; however, further hyperpolarization reduced the blockade sharply (Shin et al., 2001) . As mentioned before, several residues near the intracellular activation gate were then identified to be critical for the action of ivabradine or ZD7288 on HCN channels (Bucchi et al., 2013; Cheng et al., 2007) . Our study shows that the action of carvedilol on HCN channels is distinct from that of ivabradine or ZD7288.
The similar sensitivity of WT and mutant (A425G and F431A) HCN2 channels to carvedilol indicates carvedilol interacts with distinct regions compared with ivabradine and ZD7288. Based on the dramatic modulation of voltage-dependent gating and activation/deactivation kinetics by carvedilol, we propose here that the compound is a negative gating modulator rather than a simple pore blocker of HCN channels. In addition, as a gating modifier, carvedilol also reduces the maximal open probability of HCN channels to different extents depending on the subtype. Niflumic acid has also been reported to act as a negative gating modifier of HCN channels (Accili and DiFrancesco, 1996; Satoh and Yamada, 2001 ). Cheng and Sanguinetti (2009) found that niflumic acid inhibited HCN2 channels by interacting with the outer region of the S4 voltage-sensing domain. Taken together, these findings indicate that future thorough mutational analysis throughout the voltage sensor domains (mainly S1-S2 and S4) is needed to identify the putative binding sites of carvedilol in HCN channels.
Clinical implications
CHF is a major public health concern associated with a high prevalence and poor clinical outcomes (Yancy et al., 2013) . In the USA, CHF is the leading cause of hospitalization among adults older than 65 years of age (Desai and Stevenson, 2012 ). An increased heart rate is a risk factor for heart failure, and a reduction in the elevated basal heart rate can benefit these patients and prolong their lifespan (Benetos et al., 1999; Perret-Guillaume et al., 2009) . β-Blockers can obviously reduce heart rate, but their use is limited by adverse effects, including negative inotropic and BP-lowering effects (Doesch et al., 2007) . In addition to carvedilol, we tested the effects of three other known β-blockers (metoprolol, bisoprolol and labetalol) on the HCN4 channel and found that only carvedilol effectively inhibited this channel. During the therapeutic application of carvedilol, plasma concentrations of the drug are between 0.1 and 0.6 μM (Karle et al., 2001) , while the concentrations of carvedilol in the heart are fivefold to sevenfold higher than in the plasma due to its high degree of lipophilicity and the large volume of distribution of the drug (Fujimaki, 1992; Stahl et al., 1993; Caron et al., 1999; Karle et al., 2001) . This suggests a possible therapeutic relevance of the blockade by carvedilol of HCN currents.
In conclusion, our study demonstrated that carvedilol is a negative gating modulator of HCN channels. It may represent a novel structure for future drug design of HCN channel inhibitors.
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